This report is an updated version of the report published on 9 September 2026 at 2:44 PM AEST.

1.1: Company Overview: Recce Pharmaceuticals Limited (ASX:RCE) is an Australian biotechnology company developing a new class of synthetic anti-infectives to address antibiotic-resistant superbugs and emerging viral infections. Its pipeline includes RECCE® 327 for severe bacterial infections, RECCE® 435 as an oral anti-bacterial therapy, and RECCE® 529 targeting viral infections. Through multi-layered mechanisms of action, the company’s synthetic polymer platform is designed to overcome resistance mechanisms that limit the effectiveness of conventional antibiotics. Kalkine’s Healthcare Report covers the Investment Highlights, Management Insights, Key Financial Metrics, Risks, Technical Analysis along with the TTM-based Valuation, Target Price, and Recommendation on the stock.

Past performance is not a reliable indicator of future performance.